Recently, BeOne Medicines Ltd. announced that its independently developed next-generation BCL2 inhibitor sonrotoclax (BEQALZI™) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) who have previously received at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. This approval not only marks the first approval of a novel BCL2 inhibitor in the United States in the past decade, but also makes sonrotoclax the only BCL2-targeted therapy currently approved in the U.S. for the treatment of mantle cell lymphoma, providing a new therapeutic option for patients with limited later-line treatment choices.

Mantle cell lymphoma is a rare and aggressive subtype of non-Hodgkin lymphoma characterized by rapid disease progression and a high rate of relapse. Although BTK inhibitors have improved patient outcomes to some extent, many patients eventually develop drug resistance and disease progression. In particular, treatment options remain extremely limited after failure of BTK inhibitor therapy, and the prognosis for these patients remains poor. As a result, the development of novel targeted therapies with new mechanisms of action has become an important focus in this field.

Studies have shown that most MCL patients exhibit high expression of the BCL2 protein, making it a promising therapeutic target. As a next-generation highly selective BCL2 inhibitor, sonrotoclax was specifically optimized during its molecular design stage to enhance both potency and target selectivity, with the aim of improving antitumor activity, tolerability, and dosing convenience. The drug works by specifically binding to the BCL2 protein and blocking its anti-apoptotic function, thereby inducing tumor cell apoptosis.

The FDA’s accelerated approval was primarily based on results from the Phase 1/2 BGB-11417-201 study (NCT05471843). The study enrolled R/R MCL patients who had previously received anti-CD20 monoclonal antibody therapy and at least one BTK inhibitor. Data showed that sonrotoclax monotherapy achieved an overall response rate (ORR) of 52%, with a complete response (CR) rate of 16%. The median time to response (TTR) was only 1.9 months, indicating a rapid onset of action, while the median duration of response (DOR) reached 15.8 months, demonstrating durable disease control. In addition, the drug exhibited a favorable overall safety profile, with no new safety signals observed.

Under the FDA’s accelerated approval pathway, continued approval for this indication will depend on verification of clinical benefit in the ongoing confirmatory CELESTIAL-RRMCL trial. Previously, the FDA had granted sonrotoclax Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation to facilitate its development and regulatory review.

Notably, sonrotoclax has already been approved in China for the treatment of R/R MCL as well as adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have previously received systemic therapy including a BTK inhibitor. Regulatory authorities including the European Medicines Agency (EMA) are also reviewing the corresponding marketing applications.

Industry observers believe that the FDA approval of sonrotoclax not only introduces a new BCL2-targeted treatment option for MCL, but also highlights the growing global competitiveness of Chinese innovative pharmaceutical companies in hematologic oncology drug development. Meanwhile, BeOne is continuing to explore combination therapies involving sonrotoclax and other agents such as zanubrutinib, with related data expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The compound PCT application for sonrotoclax was filed as WO2019210828A1 and has entered national phases in 31 countries or regions, including China, the United States, the European Union, Japan, South Korea, Australia, and Canada. The patent has already been granted by the five major patent offices in China, the United States, Europe, Japan, and South Korea. In China, the granted patent was published under authorization number CN112437772B. The patent family has a filing date of April 29, 2019, with an estimated expiration date of April 29, 2039. Given that the patent has secured protection across multiple major jurisdictions, it appears to possess relatively strong inventiveness and is expected to provide BeOne with a long-term period of market exclusivity, with approximately 13 years of patent life remaining.